Safety concerns continue to plague Roche’s BTK inhibitor in RMS
Roche’s BTK inhibitor, fenebrutinib, cuts relapse rates in patients with relapsing multiple sclerosis (RMS), but safety concerns continue…
Novartis presents new data on early symptom relief and long-term control in complex skin diseases at AAD 2026
Novartis Pharma AG New Rhapsido® REMIX-1 & -2 pooled analysis on symptom control as early as week 1…